FDA Clears Novo Nordisk's Higher-Dose Wegovy in 54 Days

The FDA cleared Wegovy HD, a 7.2 mg dose of semaglutide, in just 54 days — the fourth approval under Commissioner Martin Makary’s National Priority Voucher pilot program. Novo Nordisk gets an expanded label on one of pharma’s most profitable franchises.

The CNPV program fast-tracks products tied to “national health priorities,” a deliberately broad category that includes obesity treatment. Novo applied, got the voucher, and now has a higher-dose option that clinical data shows delivers greater average weight loss than existing doses. It’s the same GLP-1 receptor agonist, just pushed further.

A higher-dose option gives Novo room to grow the Wegovy franchise without launching a new molecule, while insurers and PBMs will be watching whether “more effective” translates to higher list prices.

There’s one wrinkle: the FDA is investigating reports of altered skin sensation, including pain and burning, that occurred more frequently at the higher dose. The FDA notes the reaction generally resolved on its own or with dose reduction.

The FDA holds a public hearing on the CNPV program in June.